C4: 2024 Priorities and Extended Cash Runway, at JP Morgan

 Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials

Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused Discovery Research Efforts Results in Workforce Reduction of Approximately 30%

Unaudited Cash, Cash Equivalents and Marketable Securities Totaling Approximately $330 million as of January 5, 2024, Combined with Cost Savings from Restructured Operations, Results in Cash Runway into 2027

Company to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11

C4T will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 am PST (12:00 pm EST). A live webcast will be available under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.

https://www.globenewswire.com/news-release/2024/01/09/2806663/0/en/C4-Therapeutics-Announces-2024-Priorities-and-Extended-Cash-Runway-to-Advance-Portfolio-of-Targeted-Protein-Degradation-Medicines.html